Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rusalatide - Chrysalis BioTherapeutics

Next Previous
X
Search
Drug Profile

Rusalatide - Chrysalis BioTherapeutics

Alternative Names: Chrysalin; Rusalatide acetate; Thrombin receptor activating peptide; TP 508; TRAP-508

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Medical Branch
  • Developer Baylor College of Medicine; Capstone Therapeutics; Chrysalis BioTherapeutics; Quintiles; University of Texas Medical Branch
  • Class Amino acids; Peptides; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome
  • No development reported Acute radiation syndrome
  • Discontinued Chronic wounds; Diabetic foot ulcer; Fracture; Joint disorders; Myocardial infarction; Periodontal disorders; Spinal disorders; Vascular disorders

Most Recent Events

  • 06 May 2024 Preclinical trials in Adult respiratory distress syndrome in USA (unspecified route) prior to May 2024
  • 26 Sep 2023 US FDA approves IND application for Rusalatide in Acute respiratory distress syndrome
  • 26 Sep 2023 Chrysalis BioTherapeutics plans a phase I trial for Acute respiratory distress syndrome in December 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top